Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer.

Zhang H, Christensen CL, Dries R, Oser MG, Deng J, Diskin B, Li F, Pan Y, Zhang X, Yin Y, Papadopoulos E, Pyon V, Thakurdin C, Kwiatkowski N, Jani K, Rabin AR, Castro DM, Chen T, Silver H, Huang Q, Bulatovic M, Dowling CM, Sundberg B, Leggett A, Ranieri M, Han H, Li S, Yang A, Labbe KE, Almonte C, Sviderskiy VO, Quinn M, Donaghue J, Wang ES, Zhang T, He Z, Velcheti V, Hammerman PS, Freeman GJ, Bonneau R, Kaelin WG Jr, Sutherland KD, Kersbergen A, Aguirre AJ, Yuan GC, Rothenberg E, Miller G, Gray NS, Wong KK.

Cancer Cell. 2020 Jan 13;37(1):37-54.e9. doi: 10.1016/j.ccell.2019.11.003. Epub 2019 Dec 26.

PMID:
31883968
2.

Outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic NSCLC at US oncology practices.

Velcheti V, Chandwani S, Chen X, Pietanza MC, Piperdi B, Burke T.

Immunotherapy. 2019 Dec;11(18):1541-1554. doi: 10.2217/imt-2019-0177. Epub 2019 Nov 27.

3.

In Vivo Epigenetic CRISPR Screen Identifies Asf1a as an Immunotherapeutic Target in Kras-Mutant Lung Adenocarcinoma.

Li F, Huang Q, Luster TA, Hu H, Zhang H, Ng WL, Khodadadi-Jamayran A, Wang W, Chen T, Deng J, Ranieri M, Fang Z, Pyon V, Dowling CM, Bagdatlioglu E, Almonte C, Labbe K, Silver H, Rabin AR, Jani K, Tsirigos A, Papagiannakopoulos T, Hammerman PS, Velcheti V, Freeman GJ, Qi J, Miller G, Wong KK.

Cancer Discov. 2019 Nov 19. doi: 10.1158/2159-8290.CD-19-0780. [Epub ahead of print]

PMID:
31744829
4.

Changes in CT Radiomic Features Associated with Lymphocyte Distribution Predict Overall Survival and Response to Immunotherapy in Non-Small Cell Lung Cancer.

Khorrami M, Prasanna P, Gupta A, Patil P, Velu PD, Thawani R, Corredor G, Alilou M, Bera K, Fu P, Feldman M, Velcheti V, Madabhushi A.

Cancer Immunol Res. 2020 Jan;8(1):108-119. doi: 10.1158/2326-6066.CIR-19-0476. Epub 2019 Nov 12.

PMID:
31719058
5.

A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.

Hida T, Velcheti V, Reckamp KL, Nokihara H, Sachdev P, Kubota T, Nakada T, Dutcus CE, Ren M, Tamura T.

Lung Cancer. 2019 Dec;138:124-130. doi: 10.1016/j.lungcan.2019.09.011. Epub 2019 Sep 16.

6.

Author Correction: Quantitative vessel tortuosity: A potential CT imaging biomarker for distinguishing lung granulomas from adenocarcinomas.

Alilou M, Orooji M, Beig N, Prasanna P, Rajiah P, Donatelli C, Velcheti V, Rakshit S, Yang M, Jacono F, Gilkeson R, Linden P, Madabhushi A.

Sci Rep. 2019 Oct 29;9(1):15873. doi: 10.1038/s41598-019-52008-9.

7.

Corrigendum to "Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features" [Lung Cancer 135 (September) (2019) 1-9].

Khorrami M, Jain P, Bera K, Alilou M, Thawani R, Patil P, Ahmad U, Murthy S, Stephans K, Fu P, Velcheti V, Madabhushi A.

Lung Cancer. 2019 Oct;136:156. doi: 10.1016/j.lungcan.2019.08.012. Epub 2019 Aug 21. No abstract available.

PMID:
31564290
8.

Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features.

Khorrami M, Jain P, Bera K, Alilou M, Thawani R, Patil P, Ahmad U, Murthy S, Stephans K, Fu P, Velcheti V, Madabhushi A.

Lung Cancer. 2019 Sep;135:1-9. doi: 10.1016/j.lungcan.2019.06.020. Epub 2019 Jul 5. Erratum in: Lung Cancer. 2019 Oct;136:156.

PMID:
31446979
9.

Artificial intelligence in digital pathology - new tools for diagnosis and precision oncology.

Bera K, Schalper KA, Rimm DL, Velcheti V, Madabhushi A.

Nat Rev Clin Oncol. 2019 Nov;16(11):703-715. doi: 10.1038/s41571-019-0252-y. Epub 2019 Aug 9. Review.

10.

First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment.

Velcheti V, Chandwani S, Chen X, Pietanza MC, Burke T.

Immunotherapy. 2019 Jul;11(10):889-901. doi: 10.2217/imt-2019-0061. Epub 2019 Jun 11.

11.

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.

Thomas A, Vilimas R, Trindade C, Erwin-Cohen R, Roper N, Xi L, Krishnasamy V, Levy E, Mammen A, Nichols S, Chen Y, Velcheti V, Yin F, Szabo E, Pommier Y, Steinberg SM, Trepel JB, Raffeld M, Young HA, Khan J, Hewitt S, Lee JM.

J Thorac Oncol. 2019 Aug;14(8):1447-1457. doi: 10.1016/j.jtho.2019.04.026. Epub 2019 May 4.

PMID:
31063862
12.

Expression Analysis and Significance of PD-1, LAG-3, and TIM-3 in Human Non-Small Cell Lung Cancer Using Spatially Resolved and Multiparametric Single-Cell Analysis.

Datar I, Sanmamed MF, Wang J, Henick BS, Choi J, Badri T, Dong W, Mani N, Toki M, Mejías LD, Lozano MD, Perez-Gracia JL, Velcheti V, Hellmann MD, Gainor JF, McEachern K, Jenkins D, Syrigos K, Politi K, Gettinger S, Rimm DL, Herbst RS, Melero I, Chen L, Schalper KA.

Clin Cancer Res. 2019 Aug 1;25(15):4663-4673. doi: 10.1158/1078-0432.CCR-18-4142. Epub 2019 May 3.

PMID:
31053602
13.

Rational design of anti-GITR-based combination immunotherapy.

Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C, Yang X, Zhong H, Newman W, Qi J, Wong P, Schaer D, Koon H, Velcheti V, Hellmann MD, Postow MA, Callahan MK, Wolchok JD, Merghoub T.

Nat Med. 2019 May;25(5):759-766. doi: 10.1038/s41591-019-0420-8. Epub 2019 Apr 29.

PMID:
31036879
14.

EZH2 Inhibitors: Take It EZy, It Is All About Context.

Velcheti V, Wong KK, Saunthararajah Y.

Cancer Discov. 2019 Apr;9(4):472-475. doi: 10.1158/2159-8290.CD-19-0090.

PMID:
30936220
15.

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC).

Carvajal-Hausdorf D, Altan M, Velcheti V, Gettinger SN, Herbst RS, Rimm DL, Schalper KA.

J Immunother Cancer. 2019 Mar 8;7(1):65. doi: 10.1186/s40425-019-0540-1.

16.

Perinodular and Intranodular Radiomic Features on Lung CT Images Distinguish Adenocarcinomas from Granulomas.

Beig N, Khorrami M, Alilou M, Prasanna P, Braman N, Orooji M, Rakshit S, Bera K, Rajiah P, Ginsberg J, Donatelli C, Thawani R, Yang M, Jacono F, Tiwari P, Velcheti V, Gilkeson R, Linden P, Madabhushi A.

Radiology. 2019 Mar;290(3):783-792. doi: 10.1148/radiol.2018180910. Epub 2018 Dec 18.

17.

Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.

Velcheti V, Patwardhan PD, Liu FX, Chen X, Cao X, Burke T.

PLoS One. 2018 Nov 8;13(11):e0206370. doi: 10.1371/journal.pone.0206370. eCollection 2018.

18.

Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.

Khunger M, Patil PD, Khunger A, Li M, Hu B, Rakshit S, Basu A, Pennell N, Stevenson JP, Elson P, Panchabhai TS, Velcheti V.

PLoS One. 2018 Oct 25;13(10):e0197743. doi: 10.1371/journal.pone.0197743. eCollection 2018.

19.

Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash.

Patil PD, Fernandez AP, Velcheti V, Tarhini A, Funchain P, Rini B, Khasawneh M, Pennell NA.

Oncologist. 2019 Jan;24(1):4-8. doi: 10.1634/theoncologist.2018-0434. Epub 2018 Oct 24.

20.

Quantitative vessel tortuosity: A potential CT imaging biomarker for distinguishing lung granulomas from adenocarcinomas.

Alilou M, Orooji M, Beig N, Prasanna P, Rajiah P, Donatelli C, Velcheti V, Rakshit S, Yang M, Jacono F, Gilkeson R, Linden P, Madabhushi A.

Sci Rep. 2018 Oct 16;8(1):15290. doi: 10.1038/s41598-018-33473-0. Erratum in: Sci Rep. 2019 Oct 29;9(1):15873.

21.

Response.

Khunger M, Hernandez AV, Velcheti V.

Chest. 2018 Oct;154(4):993-994. doi: 10.1016/j.chest.2018.07.031. No abstract available.

PMID:
30290942
22.

Ultimate Precision: Targeting Cancer but Not Normal Self-replication.

Velcheti V, Schrump D, Saunthararajah Y.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:950-963. doi: 10.1200/EDBK_199753. Review.

23.

Novel Quantitative Imaging for Predicting Response to Therapy: Techniques and Clinical Applications.

Bera K, Velcheti V, Madabhushi A.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:1008-1018. doi: 10.1200/EDBK_199747. Review.

24.

Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non-Small Cell Lung Cancer.

Corredor G, Wang X, Zhou Y, Lu C, Fu P, Syrigos K, Rimm DL, Yang M, Romero E, Schalper KA, Velcheti V, Madabhushi A.

Clin Cancer Res. 2019 Mar 1;25(5):1526-1534. doi: 10.1158/1078-0432.CCR-18-2013. Epub 2018 Sep 10.

PMID:
30201760
25.

Phase I Trial of ALT-803, A Novel Recombinant IL15 Complex, in Patients with Advanced Solid Tumors.

Margolin K, Morishima C, Velcheti V, Miller JS, Lee SM, Silk AW, Holtan SG, Lacroix AM, Fling SP, Kaiser JC, Egan JO, Jones M, Rhode PR, Rock AD, Cheever MA, Wong HC, Ernstoff MS.

Clin Cancer Res. 2018 Nov 15;24(22):5552-5561. doi: 10.1158/1078-0432.CCR-18-0945. Epub 2018 Jul 25.

26.

Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers.

Drilon A, Lin JJ, Filleron T, Ni A, Milia J, Bergagnini I, Hatzoglou V, Velcheti V, Offin M, Li B, Carbone DP, Besse B, Mok T, Awad MM, Wolf J, Owen D, Camidge DR, Riely GJ, Peled N, Kris MG, Mazieres J, Gainor JF, Gautschi O.

J Thorac Oncol. 2018 Oct;13(10):1595-1601. doi: 10.1016/j.jtho.2018.07.004. Epub 2018 Jul 11.

27.

WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.

Velcheti V, Madison R, Ali SM, Schrock AB.

J Thorac Oncol. 2018 Jul;13(7):e122-e123. doi: 10.1016/j.jtho.2018.03.003. No abstract available.

28.

Selective RET kinase inhibition for patients with RET-altered cancers.

Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A.

Ann Oncol. 2018 Aug 1;29(8):1869-1876. doi: 10.1093/annonc/mdy137.

29.

Combination of computer extracted shape and texture features enables discrimination of granulomas from adenocarcinoma on chest computed tomography.

Orooji M, Alilou M, Rakshit S, Beig N, Khorrami MH, Rajiah P, Thawani R, Ginsberg J, Donatelli C, Yang M, Jacono F, Gilkeson R, Velcheti V, Linden P, Madabhushi A.

J Med Imaging (Bellingham). 2018 Apr;5(2):024501. doi: 10.1117/1.JMI.5.2.024501. Epub 2018 Apr 18.

30.

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.

Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP.

Lancet Oncol. 2018 May;19(5):694-704. doi: 10.1016/S1470-2045(18)30148-7. Epub 2018 Apr 5.

31.

Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.

Khunger A, Khunger M, Velcheti V.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618767611. doi: 10.1177/1753466618767611. Review.

32.

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Khunger M, Jain P, Rakshit S, Pasupuleti V, Hernandez AV, Stevenson J, Pennell NA, Velcheti V.

Clin Lung Cancer. 2018 May;19(3):e335-e348. doi: 10.1016/j.cllc.2018.01.002. Epub 2018 Jan 10.

PMID:
29433902
33.

Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead.

Patil PD, Burotto M, Velcheti V.

Expert Rev Mol Diagn. 2018 Mar;18(3):297-305. doi: 10.1080/14737159.2018.1440209. Epub 2018 Feb 15. Review.

PMID:
29430978
34.

Role of immune-checkpoint inhibitors in lung cancer.

Jain P, Jain C, Velcheti V.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465817750075. doi: 10.1177/1753465817750075. Review.

35.

Radiomics and radiogenomics in lung cancer: A review for the clinician.

Thawani R, McLane M, Beig N, Ghose S, Prasanna P, Velcheti V, Madabhushi A.

Lung Cancer. 2018 Jan;115:34-41. doi: 10.1016/j.lungcan.2017.10.015. Epub 2017 Nov 8. Review.

PMID:
29290259
36.

Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer.

Villarroel-Espindola F, Yu X, Datar I, Mani N, Sanmamed M, Velcheti V, Syrigos K, Toki M, Zhao H, Chen L, Herbst RS, Schalper KA.

Clin Cancer Res. 2018 Apr 1;24(7):1562-1573. doi: 10.1158/1078-0432.CCR-17-2542. Epub 2017 Dec 4.

37.

Reciprocal expression of INSM1 and YAP1 defines subgroups in small cell lung cancer.

McColl K, Wildey G, Sakre N, Lipka MB, Behtaj M, Kresak A, Chen Y, Yang M, Velcheti V, Fu P, Dowlati A.

Oncotarget. 2017 Aug 28;8(43):73745-73756. doi: 10.18632/oncotarget.20572. eCollection 2017 Sep 26.

38.

Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges.

Velcheti V, Pennell NA.

Ann Transl Med. 2017 Sep;5(18):378. doi: 10.21037/atm.2017.08.24. Review.

39.

Prediction of recurrence in early stage non-small cell lung cancer using computer extracted nuclear features from digital H&E images.

Wang X, Janowczyk A, Zhou Y, Thawani R, Fu P, Schalper K, Velcheti V, Madabhushi A.

Sci Rep. 2017 Oct 19;7(1):13543. doi: 10.1038/s41598-017-13773-7.

40.

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer.

Carvajal-Hausdorf DE, Mani N, Velcheti V, Schalper KA, Rimm DL.

J Immunother Cancer. 2017 Oct 17;5(1):81. doi: 10.1186/s40425-017-0285-7.

41.

To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis.

Khunger M, Calabrese C, Kontzias A, Velcheti V.

J Thorac Oncol. 2017 Sep;12(9):e147-e149. doi: 10.1016/j.jtho.2017.05.005. No abstract available.

42.

Challenges faced when identifying patients for combination immunotherapy.

Ernstoff MS, Gandhi S, Pandey M, Puzanov I, Grivas P, Montero A, Velcheti V, Turk MJ, Diaz-Montero CM, Lewis LD, Morrison C.

Future Oncol. 2017 Aug;13(18):1607-1618. doi: 10.2217/fon-2017-0218. Epub 2017 Aug 24. Review.

PMID:
28835114
43.

A case of crizotinib-induced esophageal ulcers.

Sussman TA, Khunger M, Velcheti V.

Lung Cancer Manag. 2017 Jul;6(1):5-7. doi: 10.2217/lmt-2016-0017. Epub 2017 Jul 14.

44.

Intracranial and Systemic Response to Alectinib in a Patient with RET-KIF5B Oncogenic Fusion.

Velcheti V, Ahluwalia M.

J Thorac Oncol. 2017 Jul;12(7):e98-e99. doi: 10.1016/j.jtho.2017.03.007. No abstract available.

45.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab.

Khunger M, Velcheti V.

J Thorac Oncol. 2017 Jul;12(7):e96-e97. doi: 10.1016/j.jtho.2017.03.008. No abstract available.

46.

Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States.

Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, Velcheti V.

Pharmacoeconomics. 2017 Aug;35(8):831-844. doi: 10.1007/s40273-017-0527-z.

47.

Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer.

Velcheti V, Radivoyevitch T, Saunthararajah Y.

Am Soc Clin Oncol Educ Book. 2017;37:812-824. doi: 10.14694/EDBK_174175. Review.

48.

Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.

Khunger M, Rakshit S, Pasupuleti V, Hernandez AV, Mazzone P, Stevenson J, Pennell NA, Velcheti V.

Chest. 2017 Aug;152(2):271-281. doi: 10.1016/j.chest.2017.04.177. Epub 2017 May 10. Review.

PMID:
28499515
49.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

50.

Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity.

Calabrese C, Kirchner E, Kontzias A, Velcheti V, Calabrese LH.

RMD Open. 2017 Mar 20;3(1):e000412. doi: 10.1136/rmdopen-2016-000412. eCollection 2017. Erratum in: RMD Open. 2017 Dec 6;3(2):e000412corr1. Kontzias, K [corrected to Kontzias, A].

Supplemental Content

Loading ...
Support Center